Product Name: KinSub1RDDYF
Product Number: PE-01AHG95
Size: 200 µg      Price:99.00
      $US
Peptide Name: KinSub1RDDYF

Product Use: For assaying the phosphotransferase activity of Insulin receptor-related protein (IRR, UniProt ID P14616). The KinSub1RDDYF peptide demonstrated very high phosphotransferase activity with IRR, and exhibited moderate specificity when assayed with over 200 other protein kinases. A listing of other kinases that show appreciable phosphotransferase activity towards this peptide are listed in Table 1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: KinSub1RDDYF was originally identified using a microarray with peptides that were predicted as optimal substrates for 500 human protein kinases with a proprietary algorithm developed at Kinexus with our academic partners.

Peptide Sequence: GGGERDDYFCGGGGG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1402.4 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: IRR

Scientific Background: IRR is one of several protein kinases that can phosphorylate KinSub1RDDYF. Human IRR is a receptor protein-tyrosine kinase of 1297 amino acid length, with a predicted molecular mass of 143,720 Da. It is a member of the TK group of protein kinases in the InsR family. Orthologues are highly conserved in vertebrates, including amphibians. IRR is required for the appearance of male gonads and for male sexual differentiation (1). Expression of IRR mRNA is restricted to a few tissue types and has been detected in neuronal tissues as well as in neuroblastomas. As a result of its occurrence in neuroblastomas, it has speculated that IRR may be involved in tumorigenesis. RT-PCR and solution hybridization/RNAse protection assay have shown strong coupling of IRR mRNA in 18 tumour cell lines (2). IRR has also been linked with the development of glioblastoma multiforme and lung adenocarcinomas.